These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30972872)

  • 21. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis.
    Fantuzzi F; Del Giglio M; Gisondi P; Girolomoni G
    Expert Opin Ther Targets; 2008 Sep; 12(9):1085-96. PubMed ID: 18694376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis.
    Mazur M; Karczewski J; Lodyga M; Żaba R; Adamski Z
    J Dermatolog Treat; 2015; 26(4):326-8. PubMed ID: 25424050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
    Furue K; Ito T; Furue M
    Cytokine; 2018 Nov; 111():182-188. PubMed ID: 30172115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The roles of cells and cytokines in the pathogenesis of psoriasis.
    Coimbra S; Figueiredo A; Castro E; Rocha-Pereira P; Santos-Silva A
    Int J Dermatol; 2012 Apr; 51(4):389-95; quiz 395-8. PubMed ID: 22435425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis: rationale for targeting interleukin-17.
    Girolomoni G; Mrowietz U; Paul C
    Br J Dermatol; 2012 Oct; 167(4):717-24. PubMed ID: 22716185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
    Chiricozzi A
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin (IL)-17 versus IL-27: opposite effects on tumor necrosis factor-α-mediated chemokine production in human keratinocytes.
    Fujiwara S; Nagai H; Oniki S; Yoshimoto T; Nishigori C
    Exp Dermatol; 2012 Jan; 21(1):70-2. PubMed ID: 22082171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of CD8+ T-Cells and their Cytokines in the Pathogenesis of Psoriasis.
    Volarić I; Vičić M; Prpić-Massari L
    Acta Dermatovenerol Croat; 2019 Sep; 27(3):159-162. PubMed ID: 31542059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data.
    Rongioletti F; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2014 Jun; 149(3):311-6. PubMed ID: 24819758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anthralin modulates the expression pattern of cytokeratins and antimicrobial peptides by psoriatic keratinocytes.
    Holstein J; Fehrenbacher B; Brück J; Müller-Hermelink E; Schäfer I; Carevic M; Schittek B; Schaller M; Ghoreschi K; Eberle FC
    J Dermatol Sci; 2017 Sep; 87(3):236-245. PubMed ID: 28673488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
    Kamata M; Tada Y
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32121574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis.
    Hegyi Z; Zwicker S; Bureik D; Peric M; Koglin S; Batycka-Baran A; Prinz JC; Ruzicka T; Schauber J; Wolf R
    J Invest Dermatol; 2012 May; 132(5):1416-24. PubMed ID: 22402441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
    Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
    Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy.
    Rácz E; Prens EP
    Expert Rev Mol Med; 2009 Dec; 11():e38. PubMed ID: 20003607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
    Lee TL; Tsai TF
    Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell responses in psoriasis and psoriatic arthritis.
    Diani M; Altomare G; Reali E
    Autoimmun Rev; 2015 Apr; 14(4):286-92. PubMed ID: 25445403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy.
    Johansen C; Vinter H; Soegaard-Madsen L; Olsen LR; Steiniche T; Iversen L; Kragballe K
    Br J Dermatol; 2010 Dec; 163(6):1194-204. PubMed ID: 20846304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoriasis: Recent progress in molecular-targeted therapies.
    Honma M; Hayashi K
    J Dermatol; 2021 Jun; 48(6):761-777. PubMed ID: 33404109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.